Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding

Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding

Avelumab is an IgG1 anti–programmed death ligand 1 (anti–PD-L1) monoclonal antibody that has been approved as a monotherapy for metastatic Merkel cell carcinoma and advanced urothelial carcinoma, and in combination with axitinib for advanced renal cell carcinoma. Avelumab is cleared faster and has a...

Full description

Bibliographic Details
Main Authors: Hulin Jin, Vittorio D'Urso, Berend Neuteboom, Sean D. McKenna, Rene Schweickhardt, Alec W. Gross, Yves Fomekong Nanfack, Andrea Paoletti, Carina Carter, Lars Toleikis, Markus Fluck, Juergen Scheuenpflug, Ti Cai
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
avelumab
internalization
fcγr binding
pd-l1 binding
clearance
Online Access:http://dx.doi.org/10.1080/2162402X.2021.1958590

Internet

http://dx.doi.org/10.1080/2162402X.2021.1958590

Similar Items